ExeVir Bio, a Ghent, Belgium-based biotech company developing heavy chain-only antibodies targeting highly conserved epitopes for broad protection against infectious diseases, announced the appointment of Michael Garrett as its new Chief Executive Officer, effective 1 December 2024.
He will also join ExeVir’s Board of Directors.
Mr. Garrett, a British and European Patent Attorney, holds an Honors degree in Chemistry from Southampton University, UK, and an Executive Certificate in General Management from the Cedep INSEAD business school, France.
With a background in medicinal chemistry and patent law, he co-founded Flamingo Therapeutics, negotiated deals with Ionis Pharmaceuticals, and led the company through a merger with Dynacure SA (France). He has held various executive roles in major pharma companies, overseeing business development, investments, and IP.
Prior to co-founding Flamingo Therapeutics, he was a Partner with TCG, a life science consulting group in RTP, North Carolina. He was Vice President of Corporate Development at Scynexis, Inc. and a member of the team that executed the company’s IPO. Mr. Garrett was Global Vice President, Ventures & Business Development for BTG plc, with responsibility for the company’s investment portfolio. Prior to this he worked in the corporate venture group of Aventis (Paris) and in their business development group. Earlier in his career he was a patent attorney in the Rhone-Poulenc Intellectual Property department, based in France and the UK.
FinSMEs
18/11/2024